TARO-CARBAMAZEPINE CR TABLET (EXTENDED-RELEASE)

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

CARBAMAZEPINE

זמין מ:

TARO PHARMACEUTICALS INC

קוד ATC:

N03AF01

INN (שם בינלאומי):

CARBAMAZEPINE

כמות:

200MG

טופס פרצבטיות:

TABLET (EXTENDED-RELEASE)

הרכב:

CARBAMAZEPINE 200MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

100/500

סוג מרשם:

Prescription

איזור תרפויטי:

MISCELLANEOUS ANTICONVULSANTS

leaflet_short:

Active ingredient group (AIG) number: 0108674001; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2022-02-04

מאפייני מוצר

PRODUCT MONOGRAPH
Pr
TARO- CARBAMAZEPINE TABLETS 200 MG
(CARBAMAZEPINE TABLETS, TARO STANDARD)
Pr
TARO- CARBAMAZEPINE
CHEWABLE TABLETS 100 MG AND 200 MG
(CARBAMAZEPINE CHEWABLE TABLETS)
Pr
TARO- CARBAMAZEPINE CR
TABLETS 200 MG AND 400 MG
(CARBAMAZEPINE EXTENDED-RELEASE TABLETS, TARO STANDARD)
Pr
TARO- CARBAMAZEPINE SUSPENSION 100 MG/5 ML
(CARBAMAZEPINE ORAL SUSPENSION, USP) ANTICONVULSANT
FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA
ANTIMANIC
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
August 31, 2018
Brampton, Ontario
L6T 1C1
Control No: 218942
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
5
ADVERSE REACTIONS
........................................................................................................
15
DRUG INTERACTIONS
........................................................................................................
19
DOSAGE AND ADMINISTRATION
....................................................................................
24
OVERDOSAGE
......................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 28
STORAGE AND STABILITY
................................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 30
PART II: SCIENTIFIC INFORMATION
..........................................